PhenomeX Inc. Common Stock
CELL
CELL was delisted on the 29th of September, 2023.
123 hedge funds and large institutions have $244M invested in PhenomeX Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 50 increasing their positions, 32 reducing their positions, and 25 closing their positions.
93% more call options, than puts
Call options by funds: $341K | Put options by funds: $177K
56% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 32
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
5% less funds holding
Funds holding: 130 → 123 (-7)
20% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 25
30% less capital invested
Capital invested by funds: $348M → $244M (-$104M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Glenview Capital Management
New York
|
+$5.93M |
| 2 |
NIMC
Nierenberg Investment Management Company
Camas,
Washington
|
+$4.11M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$3.18M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.43M |
| 5 |
BlackRock
New York
|
+$2.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.43M |
| 2 |
AAMU
AEGON Asset Management (UK)
Edinburgh,
United Kingdom
|
-$4.29M |
| 3 |
Morgan Stanley
New York
|
-$4.06M |
| 4 |
Two Sigma Investments
New York
|
-$3.77M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.97M |
CELL Hedge Fund Activity: Q2 2022 in Review
123 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in PhenomeX Inc. Common Stock (CELL) for Q2 2022, worth a combined $244M — down 30% from $348M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of CELL and 20 opened new positions — a net loss of 5 holders — while 32 trimmed existing stakes and 50 added.
The largest buyer was Glenview Capital Management, adding an estimated $5.93M. The largest seller was Vanguard Group, cutting an estimated $4.43M.
- 123 institutional investors held PhenomeX Inc. Common Stock (CELL) as of Q2 2022, down from 130 in Q1 2022.
- Funds reported $244M of PhenomeX Inc. Common Stock stock for Q2 2022, down 30% quarter-over-quarter.
- 20 funds opened new PhenomeX Inc. Common Stock positions in Q2 2022 and 25 closed out, a net change of -5 holders.
- The largest PhenomeX Inc. Common Stock buyer in Q2 2022 was Glenview Capital Management, an estimated $5.93M added.
- The largest PhenomeX Inc. Common Stock seller in Q2 2022 was Vanguard Group, an estimated $4.43M sold.
Based on aggregated 13F filings for Q2 2022.